Fig 1: The antiviral protective effects of BT treatment in vivo. (A) Schematic representation of a mouse model of VSV infection treated with BT in vivo. C57BL/6 mice were infected intraperitoneally (i.p.) with VSV (1 × 108 PFU per mouse), followed by daily i.p. injections of BT (10 mg/kg/day) or PBS (vehicle control) for three consecutive days. (B) Survival curves of VSV-infected mice treated with BT or PBS (n = 8 per group). Survival comparisons were performed using the log-rank (Mantel-Cox) test. (C) RT-qPCR analysis of the VSV-N mRNA levels in the blood tissues of VSV-infected mice treated with BT or not (n = 3 per group). Data normalized to ACTB and expressed as fold change relative to PBS-treated control (VSV alone, set as 1). (D) IFNB1 mRNA levels in the liver, lung, and spleen tissues harvested from C57BL/6J mice 24 h after a single i.p. injection of BT (10 mg/kg) or PBS were quantified by RT-qPCR (n = 3 per group). Data normalized to ACTB and expressed as fold change relative to PBS-treated control (Mock, set as 1). Data are presented as mean ± SEM, with n = 3. *P < 0.05; **P < 0.01; ***P < 0.001.